Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 7/20 | 0.65 |
| ▸ | MAOB | P27338 | 7/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 7/20 | 0.44 |
| ▸ | RCOR1 | Q9UKL0 | 3/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1318340 | 0.79 | MAOA (1.00) | MAOAMAOBKDM1ARCOR1LOXL2 | |
| Hydrochloric Acid SCHEMBL1318464 | 0.77 | MAOA (0.95) | MAOAMAOBKDM1ARCOR1LOXL2 | |
| SCHEMBL433971 | 0.76 | MAOA (0.83) | MAOAMAOBKDM1ARCOR1 | |
| SCHEMBL5190756 | 0.76 | MAOA (0.83) | MAOAMAOBKDM1ARCOR1 | |
| Hydrochloric Acid SCHEMBL28716487 | 0.76 | MAOA (0.91) | MAOAMAOBKDM1ARCOR1LOXL2 | |
| SCHEMBL75539 | 0.75 | HTR2A (0.43) | MAOAMAOB | |
| SCHEMBL19814603 | 0.74 | MAOA (0.65) | MAOAMAOBLMNAHTTNPSR1 | |
| Hydrochloric Acid SCHEMBL3712837 | 0.74 | MAOA (0.79) | MAOAMAOBKDM1ARCOR1 | |
| SCHEMBL8803044 | 0.74 | MAOA (0.79) | MAOAMAOBKDM1A | |
| Hydrochloric Acid SCHEMBL3967040 | 0.74 | MAOA (0.79) | MAOAMAOBKDM1ARCOR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745462-B2 | Quinoline-2-one derivatives for the treatment of airways diseases | NOVARTIS AG (CH) | 2010-06-29 | — | — | US | disclosed |
| US-20070066607-A1 | Quinoline-2-one derivatives for the treatment of airways diseases | NOVARTIS AG (CH) | 2007-03-22 | — | — | US | disclosed |
| EP-1613315-A1 | QUINOLINE-2-ONE-DERIVATIVES FOR THE TREATMENT OF AIRWAYS DISEASES | Novartis AG (CH) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004087142-A1 | QUINOLINE-2-ONE-DERIVATIVES FOR THE TREATMENT OF AIRWAYS DISEASES | NOVARTIS AG (CH) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066607-A1 | Quinoline-2-one derivatives for the treatment of airways diseases | ADRB2, ADRA2C, ADRB1 | MAOA 1176/4885MAOB 1058/4885LMNA 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.